Journal List > Korean J Urogenit Tract Infect Inflamm > v.9(1) > 1059948

Kang, Seo, and Kang: Analysis of Urinary Stone Composition: A Retrospective Single Center Study during the Last Five Years (2009-2013)

Abstract

Purpose

Analysis of urinary stone composition is essential for treatment and prevention of urolithiasis. We evaluated the effect of age, gender, and stone location on urinary stone components during the last five years.

Materials and Methods

We conducted a retrospective analysis of the medical records of 375 patients ranging in age from 15 years old to 93 years old (241 males and 134 females) who underwent conventional or endoscopic surgery, shock wave lithotripsy, or passed their stones spontaneously between 2009 and 2013. Stone analysis was performed using a chemical analysis method to determine the molecular composition of each stone.

Results

Of the 375 patients with urolithiasis, 152 patients (40.5%) had predominantly calcium oxalate, 85 patients (21.5%) had uric acid, 17 patients (4.5%) had calcium phosphate, 17 patients (4.5%) had magnesium ammonium phosphate, 16 patients (4.3%) had calcium carbonate, and 86 patients (22.9%) had mixed stone type. There was a decreasing prevalence of calcium oxalate stone with age group (42.5% in young adult (20-39 years, n=40), 45.0% in adult (40-60 years, n=151), and 32.7% in elderly (≥60 years, n=180) as opposed to increasing prevalence in uric acid stone (7.5% in young adult, 15.2% in adult and 32.2% in elderly). Uric acid stones were more common in males and in lower urinary tract stones.

Conclusions

In this study, the incidence of calcium oxalate decreased with age and that of uric acid increased with age and in male. In comparison of the results of previous studies for several decades, the incidence of uric acid increased in the last five years.

REFERENCES

1. Saita A, Bonaccorsi A, Motta M. Stone composition: where do we stand? Urol Int. 2007; 79(Suppl 1):16–9.
crossref
2. Kim Hh. Jo MK, Kwak C, Park SK, Yoo KY, Kang D, et al. Prevalence and epidemiologic characteristics of urolithiasis in Seoul, Korea. Urology. 2002; 59:517–21.
crossref
3. Johnson CM, Wilson DM, O'Fallon WM, Malek RS, Kurland LT. Renal stone epidemiology: a 25-year study in Rochester, Minnesota. Kidney Int. 1979; 16:624–31.
crossref
4. Smith LH. The medical aspects of urolithiasis: an overview. J Urol. 1989; 141:707–10.
crossref
5. Alaya A, Nouri A, Belgith M, Saad H, Jouini R, Najjar MF. Changes in urinary stone composition in the Tunisian population: a retrospective study of 1,301 cases. Ann Lab Med. 2012; 32:177–83.
crossref
6. Goldfarb DS, Coe FL. Prevention of recurrent nephrolithiasis. Am Fam Physician. 1999; 60:2269–76.
7. Kourambas J, Aslan P, Teh CL, Mathias BJ, Preminger GM. Role of stone analysis in metabolic evaluation and medical treatment of nephrolithiasis. J Endourol. 2001; 15:181–6.
crossref
8. Basiri A, Taheri M, Taheri F. What is the state of the stone analysis techniques in urolithiasis? Urol J. 2012; 9:445–54.
9. Asper R. Epidemiology and socioeconomic aspects of urolithiasis. Urol Res. 1984; 12:1–5.
crossref
10. Hesse A, Siener R. Current aspects of epidemiology and nutrition in urinary stone disease. World J Urol. 1997; 15:165–71.
crossref
11. Daudon M, Donsimoni R, Hennequin C, Fellahi S, Le Moel G, Paris M, et al. Sex- and age-related composition of 10 617 calculi analyzed by infrared spectroscopy. Urol Res. 1995; 23:319–26.
crossref
12. Byeon SS, Kim HH, Kim SW. Analysis of the urinary stone components using chemical analysis method. Korean J Urol. 1996; 37:179–86.
13. Ye SJ, Yoo ES, Park YK. Analysis of urinary stone components during the last two decades. Korean J Urol. 2007; 48:1285–88.
crossref
14. Balaji KC, Menon M. Mechanism of stone formation. Urol Clin North Am. 1997; 24:1–11.
crossref
15. Menon M, Mahle CJ. Oxalate metabolism and renal calculi. J Urol. 1982; 127:148–51.
crossref
16. Finlayson B. Symposium on renal lithiasis. Renal lithiasis in review. Urol Clin North Am. 1974; 1:181–212.
17. Siener R, Glatz S, Nicolay C, Hesse A. The role of overweight and obesity in calcium oxalate stone formation. Obes Res. 2004; 12:106–13.
crossref
18. Coe FL, Evan A, Worcester E. Kidney stone disease. J Clin Invest. 2005; 115:2598–608.
19. Abate N, Chandalia M, Cabo-Chan AV Jr, Moe OW, Sakhaee K. The metabolic syndrome and uric acid nephrolithiasis: novel features of renal manifestation of insulin resistance. Kidney Int. 2004; 65:386–92.
crossref
20. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY. Association of urinary pH with body weight in nephrolithiasis. Kidney Int. 2004; 65:1422–5.
crossref
21. Negri AL, Spivacow R, Del Valle E, Pinduli I, Marino A, Fradinger E, et al. Clinical and biochemical profile of patients with "pure" uric acid nephrolithiasis compared with "pure" calcium oxalate stone formers. Urol Res. 2007; 35:247–51.
crossref
22. Zechner O, Pfluger H, Scheiber V. Idiopathic uric acid lithiasis: epidemiologic and metabolic aspects. J Urol. 1982; 128:1219–23.
crossref
23. Poletto J, Harima HA, Ferreira SR, Gimeno SG. Hyperuricemia and associated factors: a cross-sectional study of Japanese-Brazilians. Cad Saude Publica. 2011; 27:369–78.
crossref
24. Childs MA, Mynderse LA, Rangel LJ, Wilson TM, Lingeman JE, Krambeck AE. Pathogenesis of bladder calculi in the presence of urinary stasis. J Urol. 2013; 189:1347–51.
crossref

Table 1.
Components of 375 urinary calculi and distribution according to the gender
Stone component Patients Gender
Male Female
Pure (n=289)      
   CaOx 152 (40.5) 94 (39.0) 58 (43.2)
   UA 85 (21.5) 69 (28.6) 16 (11.9)
   CaP 17 (4.5) 13 (5.3) 4 (2.9)
   MAP 17 (4.5) 9 (3.7) 8 (5.9)
   AAU 0 0 0
   Cystine 2 (0.5) 2 (0.8) 0
   CaCarb 16 (4.3) 4 (1.7) 12 (8.9)
Mixed (n=86)      
   CaOx+UA 23 (6.1) 19 (7.9) 4 (2.9)
   CaOx+CaP 6 (1.6) 3 (1.2) 3 (2.2)
   CaOx+MAP 1 (0.3) 0 1 (0.7)
   CaOx+CaCarb 14 (3.7) 8 (3.3) 6 (4.5)
   UA+CaP 2 (0.5) 2 (0.8) 0
   UA+MAP 4 (1.1) 4 (1.7) 0
   UA+Cystine 1 (0.3) 0 1 (0.7)
   UA+CaCarb 1 (0.3) 0 1 (0.7)
   CaP+Cystine 1 (0.3) 0 1 (0.7)
   CaP+CaCarb 13 (3.5) 4 (11.7) 9 (6.7)
   MAP+CaCarb 7 (1.9) 3 (1.2) 4 (3.0)
   CaOx+UA+CaCarb 2 (0.5) 2 (0.8) 0
   CaOx+CaP+CaCarb 11 (2.9) 5 (2.0) 6 (4.5)
Total 375 241 134

Values are presented as number (%). CaOx: calcium oxalate, UA: uric acid, CaP: calcium phosphate, MAP: magnesium ammonium phosphate, AAU: ammonium acid, CaCarb: calcium carbonate.

Table 2.
Distribution of urinary stone according to the age
Stone component Age
Child Young Adult Elderly
Pure        
   CaOx 3 (75.0) 17 (42.5) 68 (45.0) 59 (32.7)
   UA   3 (7.5) 23 (15.2) 58 (32.2)
   CaP 1 (25.0) 6 (15) 6 (3.9) 3 (1.6)
   MAP - 2 (5) 4 (2.6) 11 (6.1)
   AAU - - - -
   Cystine - 2 (5) - -
   CaCarb - 2 (5) 8 (5.2) 9 (5.0)
Mixed        
   CaOx+UA - 1 (2.5) 9 (5.9) 13 (7.2)
   CaOx+CaP - - 8 (5.2) 3 (1.7)
   CaOx+MAP - - 4 (2.6) -
   CaOx+CaCarb - 1 (2.5) 7 (4.6) 6 (3.3)
   UA+CaP - 1 (2.5) - 1 (0.6)
   UA+MAP - - 2 (1.3) 3 (1.7)
   UA+Cystine - 1 (2.5) - -
   UA+CaCarb - 1 (2.5) - 1
   CaP+Cystine - 1 (2.5) - -
   CaP+CaCarb - 1 (2.5) 5 (3.3) 8
   MAP+CaCarb - - -  2
   CaOx+UA+CaCarb - - - -
   CaOx+CaP+CaCarb - - - - 
Total 4 40 151 180

Values are presented as number (%). Child (0-19 years), young (20-39 years), adult (40-59 years), elderly (over 60 years). CaOx: calcium oxalate, UA: uric acid, CaP: calcium phosphate, MAP:magnesium ammonium phosphate, AAU: ammonium acid, CaCarb:calcium carbonate.

Table 3.
Distribution of urinary stone according to the location
Stone component Location
Kidney Ureter Bladder Urethra
Pure        
   CaOx 41 (35.6) 93 (50.5) 17 (24.2) 2 (33.3)
   UA 21 (18.2) 41 (22.2) 22 (31.4) 1 (16.7)
   CaP 5 (4.3) 7 (3.8) 2 (2.8) 1 (16.7)
   MAP 8 (6.9) 2 (1.0) 7 (10.0) - 
   AAU - - - -
   Cystine 2 (1.7) - - -
   CaCarb 8 (6.9) 7 (3.8) 1 (1.4) -
Mixed        
   CaOx+UA 10 (8.7) 6 (3.3) 6 (8.6) -
   CaOx+CaP - 5 (2.7) 1 (1.4) -
   CaOx+MAP - - 1 (1.4) -
   CaOx+CaCarb 6 (5.2) 5 (2.7) 4 (5.7) 1 (16.7)
   UA+CaP 1 (0.9) 1 (0.5) - -
   UA+MAP 1 (0.9) - 3 (4.3) -
   UA+Cystine - 1 (0.5) - -
   UA+CaCarb - 2 (1.1) - -
   UA+CaCarb CaP+Cystine - 1 (0.9) 2 (1.1) - - - - -
   CaP+CaCarb 3 (2.6) 5 (2.7) 3 (4.3) 1 (16.7)
   MAP+CaCarb 5 (4.3) - 2 (2.9) - 
   CaOx+UA+CaCarb 1 (0.9) 1 (0.5) - -
   CaOx+CaP+CaCarb 2 (1.7) 8 (4.3) 1 (1.4) -
Total 115 184 70 6

Values are presented as number (%). CaOx: calcium oxalate, UA: uric acid, CaP: calcium phosphate, MAP: magnesium ammonium phosphate, AAU: ammonium acid, CaCarb: calcium carbonate.

Table 4.
Compairing data - current and previous periods
    Kang et al. (present case) Byeon et al.12 Ye et al.13
A B
Duration (y) 2009-2013 1985-1995 1986-1995 1996-2005
Case (n) 375 495 301 158
Age (y) 2-93 (57.6±14.4) 2-76 (49.5±12.5) 47.2±14.5 46.0±10.2
Sex ratio (male:female) 1.8:1 1.8:1 2.04:1 1.98:1
Location - - - -
   Kidney 115 307 110 61
   Ureter 184 103 166 81
   Bladder 70 75 15 10
   Urethra 6 10 10 6
Stone analysis method   Chemical analysis Chemical analysis Louis C. Herring and Company
  Stone component          
   Pure - - - -
    CaOx 152 (40.5) 173 (46.3) 30 (10.0) 12 (7.6)
    UA 85 (21.5) 18 (3.6) 17 (5.6) 24 (15.2)
    CaP 17 (4.5) 23 (4.6) 5 (1.7) 7 (4.4)
    MAP AAU 17 (4.5) - 15 (3.0) - - - - -
    Cystine 2 (0.5) - 1 (0.3) 1 (0.6)
    CaCarb 16 (4.3) -  - - 
   Mixed        
    CaOx+UA 23 (6.1) 16 (3.2) 18 (6.0) 10 (6.3)
    CaOx+CaP CaOx+MAP 6 (1.6) 1 (0.3) 118 (23.8) 17 (3.4) 182 (60.5) 3 (1.0) 80 (50.6) 1 (0.6)
    CaOx+CaCarb 14 (3.7) - - -
    CaOx+AAU - - 2 (0.7) -
    UA+CaP 2 (0.5) 6 (1.2) - -
    UA+MAP 4 (1.1) 3 (0.6) - -
    UA+Cystine UA+CaCarb 1 (0.3) 1 (0.3) - - - - - -
    UA+AAU - - - 2 (1.3)
    CaP+Cystine 1 (0.3) - - -
    CaP+CaCarb 13 (3.5) - - -
    CaP+MAP - - 5 (1.7) 9 (5.7)
    MAP+CaCarb CaOx+Cystine 7 (1.9) - - 1 (0.2) - - - -
    CaP+MAP - 20 (4.0) - -
    CaOx+UA+CaCarb 2 (0.5) - - -
    CaOx+CaP+CaCarb 11 (2.9) - - -
    CaOx+CaP+MAP - 71 (14.3) 14 (4.7) 4 (2.5)
    CaOx+MAP+UA CaOx+CaP+UA - - 1 (0.2) 7 (1.4) - 9 (3.0) - -
    CaOx+CaP+Cys - 1 (0.2) - -
    CaOx+UA+ AAU - - 1 (0.3) 1 (0.6)
    CaOx+CaP+AAU - - 2 (0.7) -
    CaP+MAP+UA - 5 (1.0) - -
    CaP+MAP+AAU CaOx+CaP+MAP+AAU - - - - 7 (2.3) 1 (0.3) 4 (2.5) 1 (0.6)
    CaOx+CaP+UA+AAU - - 3 (1.0) 2 (1.3)
   CaOx+CaP+UA+MAP+AAU - - 1 (0.3) -

Values are presented as number (%), range (mean±standard deviation) or mean±standard deviation only.CaOx: calcium oxalate, UA: uric acid, CaP: calcium phosphate, MAP: magnesium ammonium phosphate, AAU: ammonium acid, CaCarb: calcium carbonate.

TOOLS
Similar articles